4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 3.13M | -77.12M | -110.03M | -107.49M | -3.12 |
| 2023 FY | 20.72M | -76.37M | -112.87M | -100.84M | -2.58 |
| 2024 FY | 37.00K | -141.26M | -187.84M | -160.87M | -2.98 |
| 2025 FY | 85.21M | 77.58M | -159.55M | -140.11M | -2.42 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 261.85M | 30.51M | 52.35M | 16.12M | 231.34M |
| 2023 FY | 339.89M | 32.06M | 249.11M | 14.67M | 307.83M |
| 2024 FY | 560.38M | 49.78M | 149.34M | 24.61M | 510.61M |
| 2025 FY | 566.71M | 61.05M | 60.24M | 21.41M | 505.66M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -86.69M | -11.54M | -98.22M | — | -100.65M |
| 2023 FY | -75.79M | -2.77M | -78.56M | — | 196.76M |
| 2024 FY | -134.59M | -3.79M | -138.37M | — | -99.77M |
| 2025 FY | -109.08M | -536.00K | -109.08M | — | -89.10M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 718.52M | 682.29M | — | — | — |
| 2023 FY | 792.78M | 558.34M | — | — | — |
| 2024 FY | 300.47M | 175.74M | — | — | — |
| 2025 FY | 434.48M | 395.65M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 15.00K | -47.94M | -59.46M | -54.66M | -0.98 |
| 2025 Q3 | 90.00K | -47.15M | -61.19M | -56.88M | -1.01 |
| 2025 Q4 | 85.09M | 83.11M | 14.72M | 19.40M | 0.34 |
| 2026 Q1 | 3.05M | 992.00K | -73.62M | -68.76M | -1.01 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 473.64M | 52.75M | 77.16M | 23.08M | 420.89M |
| 2025 Q3 | 423.98M | 55.00M | 48.56M | 22.26M | 368.98M |
| 2025 Q4 | 566.71M | 61.05M | 60.24M | 21.41M | 505.66M |
| 2026 Q1 | 512.91M | 61.07M | 72.49M | 20.54M | 451.84M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -43.38M | -66.00K | -43.44M | — | -63.81M |
| 2025 Q3 | -46.50M | 91.00K | -46.41M | — | -28.60M |
| 2025 Q4 | 28.55M | -631.00K | 27.92M | — | 11.69M |
| 2026 Q1 | -68.13M | — | -68.13M | — | 12.25M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 207.49M | 153.41M | — | — | — |
| 2025 Q3 | 487.74M | 461.45M | — | — | — |
| 2025 Q4 | 434.48M | 395.65M | — | — | — |
| 2026 Q1 | 633.68M | 581.73M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |